- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164968
Assessment of Respiratory Symptoms After Corticosteroid Treatment Period Using Impedance Pneumography (IP-ASTMA_2)
INTRODUCTION
Lung function assessment of preschool children is hindered by their limited co-operation in conventional tests such as peak expiratory flow (PEF) or spirometry and the methods available for younger children are, again, laborious and time consuming. However, impedance pneumography (IP) records indices of airway obstruction during normal sleep at home and has been shown accurate in wheezy preschool children (Seppä et al. J Appl Physiol 2013).
AIM OF THE STUDY
The general purpose of this study is to assess the clinical value of the information provided by overnight home recording of tidal breathing by means of IP technique in young children with asthmatic symptoms and inhaled corticosteroid (ICS) medication.
The main hypothesis is that IP measurement can distinguish between groups whose asthmatic symptoms recur or do not recur after ending the ICS drug treatment period.
METHODS
The study recruits 1-5 year old children (n=75) who have presented at the emergency room due to obstructive bronchitis and for whom an ICS drug treatment period has been prescribed based on the national guidelines.
The subjects will perform three overnight IP measurements at home at two weeks intervals close to and after ending of the treatment period.
SIGNIFICANCE OF THE STUDY
Being an affordable, simple and convenient ambulatory measurement method, IP may bring needed objectivity to asthma diagnostics and asthma drug response assessment in young children.
Study Overview
Status
Conditions
Detailed Description
QUALITY CONTROL AND QUALITY ASSURANCE
Information of study personnel and training All personnel involved with the use of the IP measurement device will be instructed by Ville-Pekka Seppä.
Protocol amendments Essential amendments in the research protocol will be reviewed by the institutional review board and informed to National Supervisory Authority of Welfare and Health (Valvira).
DATA HANDLING AND RECORD KEEPING Electronic data collection Electronic data will consist of IP recorder device data files (.ipr). Upon complete protocol execution there will be three files for each patient. These files will be stored in a computer in TAYS Allergiakeskus.
Data management Access to all collected patient information and the patient information collected before the study in the primary care centers will be accessible to RN Tiina Mäki (0503439195), MD Marita Paassilta, and MD Jussi Karjalainen of Allergiakeskus.
Research group members from TUT will have access only to data that does not enable identifying individual patients and where individual patients are referred to by participant codes.
Study subject register The study subject register will be treated per the Finnish Personal Data Act article 10.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Tampere, Finland, 33521
- TAYS Allergiakeskus
-
Tampere, Finland, 33720
- Tampere University of Technology / ELT Dept
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 1-5 yrs
- Recurrent obstructive bronchitis
- Inhaled corticosteroid treatment has been prescribed
Exclusion Criteria:
- Laryngeal disease
- Tracheobronchial malacia
- Parenchymal lung disease
- History of bronchopulmonary dysplasia
- Active implantable medical such as pacemakers
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Obstructive bronchitis
1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of IP measurement to distinguish patient subgroups
Time Frame: 1 wk before to 4 weeks after end of ICS period
|
Comparison of the measures derived from the IP measurement (the investigational device) between the subgroups in the cohort at three times: 1 wk before end of ICS period, 1-2 wk after ending ICS period, 3-4 wk after ending ICS period
|
1 wk before to 4 weeks after end of ICS period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jussi Karjalainen, MD, Tampere university Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R14027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Bronchitis
-
Parc de Salut MarCompletedObstructive Chronic Bronchitis With Acute ExacerbationSpain
-
Villa Pineta HospitalUnknownChronic Obstructive Pulmonary Disease | Chronic Bronchitis/BronchiectasisItaly
-
Felix JF HerthUnknownObstructive Chronic Bronchitis
-
AstraZenecaCompletedScientific Terminology Chronic Obstructive Pulmonary Disease (COPD) | Laymen Terminology Chronic Bronchitis and EmphysemaBulgaria, Germany, Hungary, Ukraine
-
Sheba Medical CenterUnknownChronic Obstructive Pulmonary Disease | Chronic Bronchitis
-
ThomasTruncaleBoehringer IngelheimCompletedChronic Obstructive Pulmonary Disease | Chronic BronchitisUnited States
-
Center for Veterans Research and EducationUnknownChronic Obstructive Pulmonary Disease | Chronic BronchitisUnited States
-
Adams Respiratory TherapeuticsCompletedChronic Obstructive Pulmonary Disease | Chronic BronchitisUnited States
-
Northumbria Healthcare NHS Foundation TrustNewcastle-upon-Tyne Hospitals NHS Trust; National Institute for Health Research... and other collaboratorsCompletedPulmonary Disease, Chronic Obstructive | Emphysema | Chronic Bronchitis | Pulmonary Disease, Obstructive | Chronic Bronchitis With Airways Obstruction | Chronic Bronchitis With Acute ExacerbationUnited Kingdom
-
Zhong WangNot yet recruitingChronic Obstructive Pulmonary Disease | Chronic BronchitisChina